Sanja Medenica, Vladimir Prelević, Nikola Zanković, Viviana Maggio, Manfredi Rizzo
{"title":"Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits.","authors":"Sanja Medenica, Vladimir Prelević, Nikola Zanković, Viviana Maggio, Manfredi Rizzo","doi":"10.1080/14740338.2026.2648248","DOIUrl":"10.1080/14740338.2026.2648248","url":null,"abstract":"<p><strong>Introduction: </strong>There is a lack of clinical models which include comprehensive and holistic care of patients with cardiorenometabolic diseases and isolated care of those patients usually leads to poor clinical outcomes. Cardiometabolic diseases, encompassing conditions like type 2 diabetes, obesity, and atherosclerotic cardiovascular disease, represent a major global health burden. Their frequent coexistence due to shared mechanisms necessitates an integrated care approach, reflecting a critical paradigm shift. Therefore, necessity for a new integrated clinical model which include all those specialties should be the focus of a new, modern interdisciplinary approach.</p><p><strong>Areas covered: </strong>This review synthesizes mechanistic insights, safety data, and emerging interventions for cardiorenometabolic disease management. It examines cornerstone therapies like SGLT2 inhibitors and GLP-1 receptor agonists, highlighting their profound cardiovascular, renal, and metabolic benefits. Newer dual/triple incretin therapies are also discussed for their potential in weight loss and cardioprotection. Safety considerations, including genitourinary infections and gastrointestinal intolerance, are addressed. Additionally, emerging research on gut microbiota-derived metabolites and sleep optimization as modifiable risk pathways is explored. The literature search included papers published as of July 2025, identified using PubMed.</p><p><strong>Expert opinion: </strong>We advocate a holistic, risk-adapted approach integrating pharmacologic, behavioral, and metabolic dimensions to optimize patient outcomes and truly transform cardiometabolic care.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2023-2040"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Praneeth Kudaravalli, Michael B Andrews, Douglas G Adler
{"title":"Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications.","authors":"Praneeth Kudaravalli, Michael B Andrews, Douglas G Adler","doi":"10.1080/14740338.2025.2493355","DOIUrl":"10.1080/14740338.2025.2493355","url":null,"abstract":"<p><strong>Background: </strong>Intestinal failure often necessitates teduglutide, a glucagon-like peptide-2 (GLP-2) analog that enhances intestinal adaptation by increasing absorptive surface area, thereby reducing reliance on intravenous supplementation (IVS). This study analyzes adverse drug reactions (ADRs) associated with teduglutide when used to treat short bowel syndrome (SBS) to inform clinical practice and enhance post-marketing surveillance.</p><p><strong>Research design and methods: </strong>Retrospective analysis was conducted using the FDA Adverse Event Reporting System (FAERS) database. ADRs reported from teduglutide's FDA approval in 2012 through 20 August 2024 were analyzed using descriptive statistics and presented as [N (%)] or [median (IQR)].</p><p><strong>Results: </strong>Of the 4,533 reports, 2,669 were females, and patients had a median age of 56 years, with 2,787 reports involving hospitalization and 443 associated with death. Gastrointestinal ADRs were the most frequently reported (<i>N</i> = 3,881), followed by infections (<i>N</i> = 2,273), cardiovascular events (<i>N</i> = 1,318), weight changes (<i>N</i> = 754), neuropsychiatric concerns (<i>N</i> = 651), and device-related infections (<i>N</i> = 618) were prominent. Mortality associated ADRs included infections (<i>N</i> = 222), gastrointestinal events (<i>N</i> = 172), and cardiovascular complications (<i>N</i> = 132).</p><p><strong>Conclusions: </strong>Teduglutide is associated with significant ADRs necessitating vigilant monitoring while managing SBS patients, particularly for gastrointestinal health and infection risks. FAERS data limitations restrict causality determination, highlighting the need for further research to optimize safety.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2105-2110"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system.","authors":"Rujia Zhong, Jiahao Li, Feng Zhang, Yi Guo","doi":"10.1080/14740338.2025.2493781","DOIUrl":"10.1080/14740338.2025.2493781","url":null,"abstract":"<p><strong>Background: </strong>Guillain-Barré Syndrome (GBS) is a rare but severe neurological disorder often precipitated by infections, vaccines, and potentially by certain medications. Drug-induced GBS, though less commonly reported, presents significant diagnostic and therapeutic challenges. This study investigates the correlation between various medications and the onset of GBS.</p><p><strong>Research design and methods: </strong>We conducted a retrospective pharmacovigilance analysis using data from the FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q1 2024. The analysis focused on identifying drugs frequently associated with GBS and examining the time-to-onset and severity of these events.</p><p><strong>Results: </strong>From over 17 million adverse events, 1,869 cases were identified as drug-induced GBS. Monoclonal antibodies and immunomodulators were the most frequently implicated drug classes. The median time-to-onset for GBS was within the first 30 days following drug exposure. Approximately 51.8% of the cases resulted in severe outcomes, such as hospitalization or disability. Drugs such as brentuximab vedotin and efalizumab showed strong associations with GBS occurrences.</p><p><strong>Conclusions: </strong>This study highlights the importance of monitoring for GBS symptoms following the administration of certain medications, particularly those that affect immune function, and underscores the need for healthcare providers to be aware of the potential neurological risks associated with these medications.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2117-2125"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mei Zhan, Qinran Long, Jinhan He, Litao Huang, Ran Liu, Bin Wu, Ting Xu
{"title":"Pancreatic adverse events induced by immune checkpoint inhibitors: a real-world observational study.","authors":"Mei Zhan, Qinran Long, Jinhan He, Litao Huang, Ran Liu, Bin Wu, Ting Xu","doi":"10.1080/14740338.2025.2493783","DOIUrl":"10.1080/14740338.2025.2493783","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitor (ICI)-induced pancreatic adverse events (AEs) are rare occurrences that are poorly documented in the literature.</p><p><strong>Research design and methods: </strong>We conducted a retrospective review of patients who had ICI up to June 2023. Patient follow-up was extended until death or to May 2024. The primary outcome was the incidence of severe ICI-related pancreatic AEs. Logistic regression was used to investigate the associations between clinical characteristics and severe ICI-related pancreatic AEs.</p><p><strong>Results: </strong>The study included 7,840 participants who received ICI. The study population was predominantly male (74.50%), with a median age of 59.20 years [IQR 51.90-67.70 years]. Among them, 49 patients (0.63%) developed severe ICI-related pancreatic AEs. Logistic regression revealed that pancreatic cancer (OR 5.47; [95% CI, 1.12-26.82], <i>p</i> = 0.036), lung cancer (OR 2.62; [95% CI, 1.09-6.34], <i>p</i> = 0.032), younger patients (OR 0.97; [95% CI, 0.94-0.99], <i>p</i> = 0.015), and using PD-L1 inhibitor (OR 3.09, [95% CI 1.46 to 6.52], <i>p</i> = 0.003) were associated with a higher risk of severe ICI-related pancreatic AEs.</p><p><strong>Conclusions: </strong>This study demonstrated that most ICI-related pancreatic AEs were asymptomatic. Primary tumor type, age, and ICI type may be predictive factors for severe ICI-related pancreatic AEs.</p><p><strong>Clinical trial registration: </strong>https://www.chictr.org.cn identifier is ChiCTR2300075974.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2111-2116"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A disproportionality analysis of interstitial lung disease associated with drug therapy in spontaneous adverse event reports.","authors":"Jiao Yuan, Zhiping Li, Meifang Ye, Zhiwen Fu","doi":"10.1080/14740338.2025.2494689","DOIUrl":"10.1080/14740338.2025.2494689","url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung disease (ILD) is a group of disorders characterized by inflammation and fibrosis of lung tissue that make it hard to carry oxygen. Our study aimed to comprehensively evaluate the risk of drug-induced ILD using data from the FDA Adverse Event Reporting System (FAERS) database.</p><p><strong>Research design and methods: </strong>We queried the ILD reports from 2004 to 2023. The reporting odds ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) were calculated to detect disproportionality signals for drugs associated with ILD.</p><p><strong>Results: </strong>A total of 39,332 ILD-related reports were identified. The most frequently reported drugs were Methotrexate (<i>N</i> = 1245), followed by Pembrolizumab (<i>N</i> = 1026), Amiodarone (<i>N</i> = 975), Rituximab (<i>N</i> = 915), and Doxorubicin (<i>N</i> = 911). Disproportionality analysis revealed significant signals for the top 50 drugs, including Trastuzumab deruxtecan (ROR 56.25, 95% CI 51.27-61.72; IC025 5.49), Ramucirumab (ROR 27.80, 95% CI 241.6-31.99; IC025 4.50), Amiodarone (ROR 24.35, 95% CI 22.82-25.99; IC025 4.40), Gefitinib (ROR 23.02, 95% CI 20.66-25.66; IC025 4.29), and Doxorubicin (ROR 13.99, 95% CI 13.09-14.95; IC025 3.64).</p><p><strong>Conclusions: </strong>Drug-induced ILD represents a significant challenge in clinical practice. Our findings underscore the importance of maintaining a high index of suspicion for drug-induced ILD, particularly when prescribing medications identified as having significant associations with ILD.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2211-2219"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chenhuan Xiang, Rongrong Guo, Juanjuan Ti, Shaoli Zhang, Tao Wang
{"title":"Infection-related adverse events comparison of bortezomib, carfilzomib and ixazomib: a pharmacovigilance study based on FAERS.","authors":"Chenhuan Xiang, Rongrong Guo, Juanjuan Ti, Shaoli Zhang, Tao Wang","doi":"10.1080/14740338.2025.2494692","DOIUrl":"10.1080/14740338.2025.2494692","url":null,"abstract":"<p><strong>Background: </strong>Bortezomib, carfilzomib and ixazomib are the most common proteasome inhibitors (PIs) used to treat Multiple Myeloma (MM). We conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS), aiming to offer a reference for safe and reasonable clinical use.</p><p><strong>Research design and methods: </strong>Adverse drug reaction (ADR) signals of bortezomib, carfilzomib and ixazomib were analyzed by statistical methods including Reporting Odds Ratio (ROR), Proportional Reporting Ratios (PRR), and Multi-item Gamma-Poisson Shrinker (MGPS).</p><p><strong>Results: </strong>A total of 13,977, 8263 and 13296 ADRs of bortezomib, carfilzomib and ixazomib were analyzed respectively from the FAERS database. The most frequent adverse reaction signal for bortezomib was peripheral neuropathy; for carfilzomib, it was acute kidney injury; for ixazomib, it was vomiting. Then, a total of 43, 23 and 10 infection-related adverse events of bortezomib, carfilzomib and ixazomib were analyzed. The most common infection-related adverse event for bortezomib was cytomegalovirus infection; for carfilzomib, it was bacteremia; and for ixazomib, it was conjunctivitis.</p><p><strong>Conclusions: </strong>In real-world pharmacovigilance studies, PIs are associated with infection-related adverse events, which is crucial for the safe use of PIs in the treatment of MM. However, further research is needed to validate the hypotheses generated in this study.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2201-2210"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database.","authors":"Xiaomin Dong, Guimu Guo, Jintuo Zhou, Tingting Chen, Peiguang Niu, Xiaoping Zeng, Ruoxuan Pan, Jinhua Zhang","doi":"10.1080/14740338.2026.2618005","DOIUrl":"10.1080/14740338.2026.2618005","url":null,"abstract":"<p><strong>Objective: </strong>To analyze adverse events signals linked to dipyridamole using the FDA Adverse Event Reporting System, informing safety protocols for clinical use.</p><p><strong>Methods: </strong>We retrospectively extracted AE reports linked to dipyridamole from the FAERS database, covering the period from Q1 2004 to Q4 2024. Signal detection was rigorously performed using a combination of statistical methods, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).</p><p><strong>Results: </strong>A total of 1235 patients experienced adverse events related to dipyridamole, with these events occurring 3371 times in total. The signal for Acquired von Willebrand's Disease emerged as particularly prominent, followed by Steal syndrome and Peritoneal hematoma. Additionally, signals indicating increased risks of pulmonary edema, myocardial ischemia and ischemic stroke were detected. Adverse events were common in patients aged ≥65 years, with the most prominent signal being Catheter site hematoma and Blood creatine phosphokinase MB increased. The combination of dipyridamole and other drugs was prone to bleeding adverse events, suggesting a multifaceted safety profile that warrants careful clinical consideration.</p><p><strong>Conclusions: </strong>These findings underscore the need for tailored safety monitoring strategies and more nuanced risk-benefit assessments in the clinical use of dipyridamole.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2191-2200"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The effectiveness and safety of naldemedine in treating opioid-induced constipation among non-cancer adult patients: updated meta-analysis.","authors":"Mohammad M Alnaeem, Khaled H Suleiman","doi":"10.1080/14740338.2025.2610488","DOIUrl":"10.1080/14740338.2025.2610488","url":null,"abstract":"<p><strong>Introduction: </strong>This meta-analysis evaluated the efficacy and safety of naldemedine for treating opioid-induced constipation (OIC) in non-cancer patients, focusing on SBM, serious TEAEs, GI side effects, opioid withdrawal, and other adverse events (AEs).</p><p><strong>Methods: </strong>A systematic review was conducted using PubMed, ScienceDirect, CINAHL, and the Cochrane Library. Two reviewers independently screened studies, extracted data, and assess methodological quality. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. A random-effects model was applied to analyze outcomes using Review Manager 5.3.</p><p><strong>Results: </strong>Eight RCTs from six studies were included, with 3879 patients in the intervention group and 3868 in the control group. Naldemedine significantly increased the incidence of serious TEAEs (RR = 1.07; 95% CI: 1.00-1.14, <i>p</i> < 0.05), drug-related adverse events (RR = 1.44, 95% CI: 1.26-1.65, <i>p</i> < 0.05), GI adverse events (RR = 1.61, 95% CI: 1.40-1.86, <i>p</i> < 0.0), and opioid withdrawal-related events (RR = 1.65, 95% CI: 1.42-1.91, <i>p</i> < 0.05). Specific AEs include abdominal pain (RR = 3.71, CI: 2.87-3.71, <i>p</i> < 0.01), nausea (RR = 1.51, CI: 1.38-1.65, <i>p</i> < 0.01), and diarrhea (RR = 2.57, CI: 2.08-3.16, <i>p</i> < 0.01) were also significantly higher in the naldemedine group.</p><p><strong>Conclusions: </strong>Naldemedine 0.2 mg is effective for treating OIC in non-cancer patients and is generally well tolerated, with primarily mild-moderate AEs. Further studies should explore long-term safety and comparisons with other PAMORAs.This review was registered in the PROSPERO databases (CRD42023472575).</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2067-2076"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Raffaella Di Napoli, Nunzia Balzano, Concetta Rafaniello, Paola Della Monica, Marina Di Domenico, Daniele Di Giulio Cesare, Giorgia Teresa Maniscalco, Cristina Scavone, Ugo Trama
{"title":"Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database.","authors":"Raffaella Di Napoli, Nunzia Balzano, Concetta Rafaniello, Paola Della Monica, Marina Di Domenico, Daniele Di Giulio Cesare, Giorgia Teresa Maniscalco, Cristina Scavone, Ugo Trama","doi":"10.1080/14740338.2025.2493795","DOIUrl":"10.1080/14740338.2025.2493795","url":null,"abstract":"<p><strong>Background: </strong>Monoclonal antibodies targeting CD20, such as rituximab, ocrelizumab, and ofatumumab, are crucial in managing multiple sclerosis (MS). However, they can cause hypogammaglobulinemia, increasing the risk of infections and autoimmune disorders.</p><p><strong>Research design and methods: </strong>This study describes cases of hypogammaglobulinemia in MS patients receiving anti-CD20 monoclonal antibodies, using data from the European spontaneous reporting system database, EudraVigilance.</p><p><strong>Results: </strong>A total of 135 individual case safety reports (ICSRs), covering 469 adverse drug reactions (ADRs), were retrieved. The majority of ICSRs were related to ocrelizumab (<i>N</i> = 93) and involved cases of hypogammaglobulinemia occurring in adult females. Almost 20% of ICSRs reported concomitant medications, mainly represented by antibiotics, vitamins and antiepileptics. Among the 469 ADRs, 36.8% were serious, and 66% had an unknown outcome. The most commonly reported ADRs belonged to the SOC 'Infections and infestations' and included cases of COVID-19 and respiratory tract infection. Lastly, disproportionality analysis did not show a statistically significant probability of gamma globulin reduction comparing each drug.</p><p><strong>Conclusions: </strong>The study highlights the importance of monitoring for the occurrence of hypogammaglobulinemia and infections in patients receiving ocrelizumab, ofatumumab and rituximab for MS. These ADRs can be extremely serious and highlight the need for ongoing research to optimize their safety profiles.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2127-2134"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biologic and targeted synthetic therapies in juvenile idiopathic arthritis: a review of current and emerging therapeutic agents.","authors":"Elif Kilic Konte, Umit Gul, Ece Aslan, Nergis Akay, Mehmet Yildiz, Amra Adrovic, Sezgin Sahin, Kenan Barut, Ozgur Kasapçopur","doi":"10.1080/14740338.2026.2640975","DOIUrl":"10.1080/14740338.2026.2640975","url":null,"abstract":"<p><strong>Introduction: </strong>Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, with varying clinical and immunological features. Over the last 20 years, treatment options for JIA have significantly expanded, with the development of biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs), which have substantially improved clinical outcomes.</p><p><strong>Areas covered: </strong>This review provides a comprehensive assessment of bDMARDs and tsDMARDs in the management of JIA, focusing on their therapeutic efficacy, long-term safety profiles, and evolving role in personalized treatment strategies. It integrates comparative data on safety and effectiveness from randomized controlled trials, observational cohorts, and large registry studies.</p><p><strong>Expert opinion: </strong>Despite substantial therapeutic progress, achieving sustained, drug-free remission remains a challenge for many JIA patients. Precision medicine - guided by predictive biomarkers, pharmacovigilance data, and real-world evidence - is essential for optimizing individualized care. Future efforts should prioritize the development of safer, more tolerable, and accessible therapies tailored to the unique needs of pediatric populations.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2053-2065"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}